Skip to main content
. Author manuscript; available in PMC: 2023 Oct 11.
Published in final edited form as: Immunity. 2022 Sep 16;55(10):1909–1923.e6. doi: 10.1016/j.immuni.2022.08.016

Table 1.

IBD patient demographics

CD UC


Remission (n = 25) Active (n = 11) Remission (n = 23) Active (n = 9)

Sex (% males) n = 11 (44%) n = 3 (27%) n = 13(57%) n = 3 (33%)
Age at blood draw (mean ± SD) 38.76 ± 14.18 36.18 ± 9.08 46.57 ± 18.41 40.56 ± 16.22
Previous resection (% yes) n = 5 (20%) n = 4 (36%) N/A N/A
Antidiarrheal (% yes) n = 1 (4%) N/A N/A N/A
Antibiotic (% yes) n = 1 (4%) N/A N/A N/A
Antimetabolite (% yes) n = 8 (32%) n = 4 (36%) n = 3 (13%) N/A
Biologic (% yes) n = 23 (92%) n = 9 (82%) n = 19(83%) n = 5 (56%)
Steroid (% yes) n = 3 (12%) n = 2 (18%) n = 1 (4%) n = 3 (33%)